Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP700812.RAXNV4sshnNl_y7_CmjXvfnzzRZh8w2PEBwf68vppeeBg130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP700812.RAXNV4sshnNl_y7_CmjXvfnzzRZh8w2PEBwf68vppeeBg130_provenance.
• NP886625.RAtY54cUvo5HVym5qnyGsx5u1i_uc20CJmlh4xTjZKl_s130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP886625.RAtY54cUvo5HVym5qnyGsx5u1i_uc20CJmlh4xTjZKl_s130_provenance.
• NP176326.RAcHo0zA26v17m4mpvragvMe2-JxYj3-okvEKtiGeGt8s130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP176326.RAcHo0zA26v17m4mpvragvMe2-JxYj3-okvEKtiGeGt8s130_provenance.
• NP443810.RAB8Y6YfIqRLUIVjhZKkMeDN7Hl0-TINsCS1Y6UUHbosY130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP443810.RAB8Y6YfIqRLUIVjhZKkMeDN7Hl0-TINsCS1Y6UUHbosY130_provenance.
• NP197824.RAWvIP_7yKN8kkFTTee3ivi0kOWTC1a97OiCxWqbzSqH8130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP197824.RAWvIP_7yKN8kkFTTee3ivi0kOWTC1a97OiCxWqbzSqH8130_provenance.
• NP570019.RAi0s-R__ylmdtHFH9o71v1MCvYPnGR0yVyGaSLEgjEWw130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP570019.RAi0s-R__ylmdtHFH9o71v1MCvYPnGR0yVyGaSLEgjEWw130_provenance.
• assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP647565.RAy7FVd4h4kRigYosVTG7eevJl0FFx7mJtxuZM8kmYJ8o130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP647565.RAy7FVd4h4kRigYosVTG7eevJl0FFx7mJtxuZM8kmYJ8o130_provenance.
• assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP480777.RAS-VjlKqS5o3URpuVy_YXiukO7LQazyHTWJd5HELgR2o130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP480777.RAS-VjlKqS5o3URpuVy_YXiukO7LQazyHTWJd5HELgR2o130_provenance.
• NP305887.RAm5IatmevTGiV2XoF5g-RqV5Xcj7fFKbsGVNp-sexH2k130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP305887.RAm5IatmevTGiV2XoF5g-RqV5Xcj7fFKbsGVNp-sexH2k130_provenance.
• NP558428.RAv2Y4wCaePG7yXdm0cgbaw4Nsa3_sc4DburE1QQdu1zc130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP558428.RAv2Y4wCaePG7yXdm0cgbaw4Nsa3_sc4DburE1QQdu1zc130_provenance.
• NP480776.RAsmV_d9-K10uH_Htc3KkOvuh55HCWqQx6s6TNEpQFqAY130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP480776.RAsmV_d9-K10uH_Htc3KkOvuh55HCWqQx6s6TNEpQFqAY130_provenance.
• NP305873.RA9Sr-bz8CVPDC9pMoZ3I5JiVHlPE5_AJwwpQkzynwPRg130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP305873.RA9Sr-bz8CVPDC9pMoZ3I5JiVHlPE5_AJwwpQkzynwPRg130_provenance.
• NP555550.RANCXmmGyaiWJwnYWwlaTUtM2ivt_q4-7Kj7wlbIZKVoY130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP555550.RANCXmmGyaiWJwnYWwlaTUtM2ivt_q4-7Kj7wlbIZKVoY130_provenance.
• NP480779.RAH9WJAL-WRw4nWWAb0kVZOKFIpXWOyVy6d3zrz8S0qp0130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP480779.RAH9WJAL-WRw4nWWAb0kVZOKFIpXWOyVy6d3zrz8S0qp0130_provenance.
• NP480775.RA30J6VYSfZNvo5nrbKLOLJ1tVWxkXjr2dBAS1wNTU0XU130_assertion description "[Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP480775.RA30J6VYSfZNvo5nrbKLOLJ1tVWxkXjr2dBAS1wNTU0XU130_provenance.